Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2019 | 2016
Number of items: 3.

2019

Fraser, G., Cramer, P., Demirkan, F., Silva, R. Santucci, Grosicki, S., Pristupa, A., Janssens, A., Mayer, J., Bartlett, N. L., Dilhuydy, M-S, Pylypenko, H., Loscertales, J., Avigdor, A., Rule, S., Villa, D., Samoilova, O., Panagiotidis, P., Goy, A., Pavlovsky, M. A., Karlsson, C., Hallek, M., Mahler, M., Salman, M., Sun, S., Phelps, C., Balasubramanian, S., Howes, A. and Chanan-Khan, A. (2019). Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia, 33 (4). S. 969 - 981. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

2016

Cramer, P., Fraser, G., Chanan-Khan, A., Demirkan, F., Silva, Santucci R., Pylypenko, H., Grosicki, S., Janssens, A., Pristupa, A., Mayer, J., Dilhuydy, M. -S, Loscertales, J., Goy, A., Avigdor, A., Rule, S., Phelps, C., Mahler, M., Salman, M., Howes, A., Balasubramanian, S. and Hallek, M. (2016). Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. Oncol. Res. Treat., 39. S. 34 - 36. BASEL: KARGER. ISSN 2296-5262

Fraser, G., Cramer, P., Demirkan, F., Santucci Silva, R., Grosicki, S., Janssens, A., Mayer, J., Dilhuydy, M. S., Pylypenko, H., Loscertales, J., Goy, A., Avigdor, A., Rule, S., Phelps, C., Mahler, M., Salman, M., Howes, A. and Hallek, M. (2016). IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY. Haematologica, 101. S. 150 - 152. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

This list was generated on Sun Mar 7 02:30:01 2021 CET.